- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04610424
Cooperative Parent Mediated Therapy in Children With Fragile X Syndrome and Williams Syndrome
Fragile X Syndrome (FXS) and Williams-Beuren Syndrome (WBS) are relatively rare disorders characterized by developmental delay associated to socio-communicative deficit and autistic-like behaviours.
WBS has been considered for a long time as the "polar opposite" of ASD, given their hypersociable phenotype. Nonetheless, recent researches have emphasized similarities between ASD and WBS phenotypes. By following some authors "social abnormalities in ASD and WS can be characterized in terms of analogous difficulties in social cognition), and distinct patterns of social motivation which appears to be reduced in ASD and enhanced in WBS". More than opposite condition, these authors suggests that WBS and ASD could share the same difficult in comprehension of social relationship, with opposite pattern of social engagement (enhanced in WBS and weakened ASD). Given, these similarities authors suggest testing the feasibility and validity of therapy for ASD in children with WBS. Parent Mediated Therapy (PMT) is a group of "technique-focused interventions where the parent is the agent of change and the child is the direct beneficiary of treatment". PMT demonstrated evidence of effectiveness in socio-communicational improvement for children with ASD in a randomized controlled trial (RCT).
Some recent researchers have extended the use of PMT to children with genetic disorders and autistic features, such as FXS. While showing encouraging results, the samples of research were limited.
They main aim of this research is to to verify effectiveness of Cooperative PMT (CMPT) for socio-communicative deficit in children with FXS and WBS. Our hypothesis is that CPMT, in addition to conventional rehabilitation therapies (mainly speech therapy and occupational therapies), could contribute to the enhancement of socio-communicative skills and the reduction of behavioural problems. We also expected also an improvement in family quality of life and a reduction of parental stress.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Fragile X Syndrome (FXS) and Williams-Beuren Syndrome (WBS) are relatively rare disorders characterized by developmental delay associated to socio-communicative deficit and autistic-like behaviours. FXS is one of the most common monogenetic cause of syndromic Autism Spectrum Disorder (ASD); up to 60% of males with FXS meet criteria for ASD. Furthermore, around 30%- 35% of children with WBS meet criteria for ASD. WBS has been considered for a long time as the "polar opposite" of ASD, given their hypersociable phenotype and their abnormal interest in social engagement. Nonetheless, recent researches have emphasized similarities between ASD and WBS phenotypes. By following Vivanti "social abnormalities in ASD and WS can be characterized in terms of analogous difficulties in social cognition (the ability to read others' behaviour), and distinct patterns of social motivation (the propensity for social approach/engagement) which appears to be reduced in ASD and enhanced in WS". More than opposite condition, VIvanti suggests that WBS and ASD could share the same difficult in comprehension of social relationship, with opposite pattern of social engagement (enhanced in WBS and weakened ASD). Moreover, some researches showed that children with WS were similarly delayed in global adaptive functioning when compared to ones with ASD. Given, these similarities authors suggest to test the feasibility and validity of therapy for ASD in children with WBS. Parent Mediated Therapy (PMT) is a group of "technique-focused interventions where the parent is the agent of change and the child is the direct beneficiary of treatment". Italian Guidelines for ASD highlight the importance of PMT for ASD treatment. PMT is also strongly recommended by NICE Clinical Guideline CG170 and WHO Mental Health Gap Action Program. PMT has showed evidence of effectiveness in short and long-term symptom reduction in young children with ASD. A research project on the effectiveness of PMT for children with ASD has been activated since 10 years at the Bambino Gesù Children Hospital (BGCH) in Rome. In last years, a semi-manualized intervention called "Cooperative Parent Mediated Therapy" (CPMT) has been systematized. Following Bearss' Parent Training taxonomy, CPMT is a targeted parent-mediated intervention focused on the ASD core symptoms. CPMT is based on the most significant models of parent training for ASD, in the perspective of Naturalistic Developmental Behavioral Interventions-NDBI with specific attention to the promotion of cooperative interactions. The aim of CPMT is to improve parental skills, to enable parents promoting the following seven target skills in their child: socio-emotional engagement, emotional regulation, imitation, communication, joint attention, play and cognitive flexibility and cooperative interaction. An individualized treatment plan is designed for each child in order to determine his developmental level and treatment goals. CMPT usually last 6 months, for a total amount of 15 sessions of 90 min; twelve core sessions (one session per week) are delivered in the first 3 months, followed by 3 monthly booster sessions. Each weekly core session had a specific focus and specific intervention strategies based on active parent coaching during parent-child interaction, and included the parent-child dyad with the parent being actively coached by a trained therapist. Live active coaching increases parents' competence in implementing strategies to enhance child development, and at the same time increases their confidence. This intervention has demonstrated evidence of effectiveness in socio-communicational improvement as measured by ADOS-G in a randomized controlled trial (RCT). On this purpose, some recent researchers have extended the use of PMT to children with genetic disorders and autistic features, such as Fragile X Syndrome (Vismara et al., 2019). While showing encouraging results, the samples of research were limited (four participants); moreover, parent coaching took place mainly through digital services (e.g. video call). Authors suggest implementing RCTs with larger samples in order to evaluate validity of PMT for individuals with FXS. Moreover, as far as we know, there are currently no researches of PMT in patients with WBS.
Since 2017, an experimental, non-pharmacological, randomized, controlled monocentric and non-profit study was started at BGCH in order to verify effectiveness of CPMT for socio-communicative deficit in children with FXS and WBS. Our hypothesis is that CPMT, in addition to conventional rehabilitation therapies (mainly speech therapy and occupational therapies), could contribute to the enhancement of socio-communicative skills and the reduction of behavioural problems. We also expected also an improvement in family quality of life and a reduction of parental stress. The intervention is provided by psychologists with specific training and expertise in CPMT and monitored through supervision by a senior child psychiatrist
Assessment: Children and their family will be evaluated at two time-points, pre randomization (T0) and six months later, at the end of control/treatment period (T1), by means of following assessment tools :
Children: 1. Cognitive Level: Leiter 3/Griffiths III; appropriate tool will be used by evaluation of developmental level 2. Adaptive Level: Vineland Adaptive Behavior Scales, Second Edition; 3. Socio-communication skills: Early Social Communication Scales; the questionnaire Skills Socio-Conversational of the Child (Le abilità socio-conversazionali del bambino; ASCB) ; 4. Language level: Italian adaptation of "MacArthur-Bates Communicative Development Inventories". - Il Primo Vocabolario del Bambino; 5. Behavioural problem: Child Behavior Checklist; 6. Clinical improvement: Clinical Global Impression - Severity scale; Clinical Global Impression - Improvement scale
Parents: 1. Parental Stress: Parenting Stress Index-Short Form; 2. Parental Quality of Life: WHO Quality of Life
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Paolo Alfieri, PhD, MD
- Phone Number: 0668594721
- Email: paolo.alfieri@opbg.net
Study Locations
-
-
-
Roma, Italy, 00146
- Recruiting
- Ospedale Pediatrico Bambino Gesù
-
Contact:
- Paolo Alfieri, MD-PhD
- Phone Number: 0668594721
- Email: paolo.alfieri@opbg.net
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Molecularly confirmed diagnosis of Fragile X Syndrome
- Molecularly confirmed diagnosis of Williams-Beuren Syndrome
- Autism features
- Score > or = 4 in Clinical Global Impression (Guy et al., 1976)
Exclusion Criteria:
- Parent yet enrolled in a parent training during first evaluation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cooperative Parent Mediated Therapy
Cooperative Parent Mediated Therapy" (CPMT) is a targeted parent-mediated intervention focused on the ASD core symptoms (Bearss et al., 2015).
CPMT is based on the most significant models of parent training for ASD, in the perspective of Naturalistic Developmental Behavioral Interventions-NDBI with specific attention to the promotion of cooperative interactions (Schreibman et al., 2016).
The aim of CPMT is to improve parental skills, to enable parents promoting the following seven target skills in their child: socio-emotional engagement, emotional regulation, imitation, communication, joint attention, play and cognitive flexibility and cooperative interaction.
An individualized treatment plan is designed for each child in order to determine his developmental level and treatment goals (Valeri et al., 2019).
|
CMPT usually last 6 months, for a total amount of 15 sessions of 90 min; twelve core sessions (one session per week) are delivered in the first 3 months, followed by 3 monthly booster sessions.
Each weekly core session had a specific focus and specific intervention strategies based on active parent coaching during parent-child interaction, and included the parent-child dyad with the parent being actively coached by a trained therapist.
Live active coaching increases parents' competence in implementing strategies to enhance child development, and at the same time increases their confidence.
This intervention has demonstrated evidence of effectiveness in socio-communicational improvement as measured by ADOS-G (Valeri, 2019) in a randomized controlled trial (RCT).
Speech Language Therapy and Occuapational Therapy provided as usual by National Health Services
|
Active Comparator: Control
Control group
|
Speech Language Therapy and Occuapational Therapy provided as usual by National Health Services
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Joint attention
Time Frame: 6 months
|
Joint attention score from ESCS assessment.
Score expressed in percentage of behavior/number of occasion (from 0% to 100%).
Higher scores indicate better functioning
|
6 months
|
Assertivity
Time Frame: 6 months
|
Assertivity as measured by Skills Socio-Conversational of the Child.
Scores from 1 to 5 (Higher scores indicate better functioning)
|
6 months
|
Responsivity
Time Frame: 6 months
|
Assertivity as measured by Skills Socio-Conversational of the Child.
Scores from 1 to 5 (Higher scores indicate better functioning)
|
6 months
|
Expressive language (Word)
Time Frame: 6 months
|
Expressive language as measured by word production scale of Primo vocabolario del bambino (from 0 to 408).
higher raw scores indicate higher level of language
|
6 months
|
Expressive language (Gestures)
Time Frame: 6 months
|
Expressive language as measured by gestures production scale of Primo vocabolario del bambino (from 0 to 63). higher raw scores indicate higher level of language
|
6 months
|
Receptive Language (Word)
Time Frame: 6 months
|
Receptive language as measured word comprehension scale of Primo vocabolario del bambino (from 0 to 408).
higher raw scores indicate higher level of language
|
6 months
|
Receptive Language (Sentences)
Time Frame: 6 months
|
Receptive language as measured by sentence comprehension scale of Primo vocabolario del bambino (from 0 to 28). higher raw scores indicate higher level of language
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Behavioral and emotional problem
Time Frame: 6 months
|
Behavioral and emotional problems as measurd by Child Behavior Checklist (T-scores, Mean 50, standard deviation 15).
Higher scores indicate severe problems.
>64 borderline >70 clinical
|
6 months
|
Change in Adaptive Level (Vineland Adaptive Behavior Scales, Second Edition)
Time Frame: 6 months
|
Adaptive functioning of children.
Scores are expressed in standard scores (mean 100, Standard deviation 15).
Higher scores indicate better functioning.
|
6 months
|
Clinical improvement: Clinical Global Impression - Severity scale
Time Frame: 6 months
|
Clinical Global Impression - Severity scale is a 7-point scale used to measure baseline severity of patients (Higher scores indicate more severe patient.
|
6 months
|
Clinical Global Impression - Improvement scale (CGI-I)
Time Frame: 6 months
|
Clinical Global Impression - Improvement scale (CGI-I) s a 7-point scale used to measure improvement after treatment (Higher scores indicate more severe symptoms)
|
6 months
|
Cognitive/developmental Level
Time Frame: 6 months
|
Developmental/cognitive level of children as measured by Leiter 3 /Griffiths III.
Scores are expressed in standard scores (mean 100, Standard deviation 15).
Higher scores indicate better functioning
|
6 months
|
Quality of Life (Social Relationship) of parents
Time Frame: 6 momths
|
Quality of life (Social Relationship) as measured by (WHOQOL).
Scores are expressed in raw scores from 0 to 100 (higher scores indicate better quality of life.
|
6 momths
|
Quality of Life (Environmental) of parents
Time Frame: 6 momths
|
Quality of life (Environmental) as measured by (WHOQOL).
Scores are expressed in raw scores from 0 to 100 (higher scores indicate better quality of life.
|
6 momths
|
Quality of Life (Fisical) of parents
Time Frame: 6 momths
|
Quality of life (Fisical) as measured by (WHOQOL).
Scores are expressed in raw scores from 0 to 100 (higher scores indicate better quality of life.
|
6 momths
|
Quality of Life (Psychological) of parents
Time Frame: 6 momths
|
Quality of life (Psychological) as measured by (WHOQOL).
Scores are expressed in raw scores from 0 to 100 (higher scores indicate better quality of life.
|
6 momths
|
Change in Parenting Stress (Parental Distress)
Time Frame: 6 months
|
Parenting Stress as measured by Parendal Distress Scale of Parenting Stress Index Short Form.
Scores are expressed in percentile (from 5° to 100°).
Higher scores indicate higher level of stress
|
6 months
|
Change in Parenting Stress (Difficult Child)
Time Frame: 6 months
|
Parenting Stress as measured by Difficult Child Scale of Parenting Stress Index Short Form.
Scores are expressed in percentile (from 5° to 100°).
Higher scores indicate higher level of stress
|
6 months
|
Change in Parenting Stress (Parent-Child Dysfunctional Interaction)
Time Frame: 6 months
|
Parenting Stress as measured by Parent-Child Dysfunctional Interaction Scale of Parenting Stress Index Short Form.
Scores are expressed in percentile (from 5° to 100°).
Higher scores indicate higher level of stress
|
6 months
|
Change in Parenting Stress (Total Score)
Time Frame: 6 months
|
Parenting Stress as measured by Total Stress Scale of Parenting Stress Index Short Form.
Scores are expressed in percentile (from 5° to 100°).
Higher scores indicate higher level of stress
|
6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Paolo Alfieri, PhD, MD, Ospedale Pediatrico Bambino Gesù
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Disease
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Aortic Valve Disease
- Heart Valve Diseases
- Mental Retardation, X-Linked
- Intellectual Disability
- Heredodegenerative Disorders, Nervous System
- Chromosome Disorders
- Sex Chromosome Disorders
- Aortic Valve Stenosis
- Aortic Stenosis, Supravalvular
- Syndrome
- Fragile X Syndrome
- Williams Syndrome
Other Study ID Numbers
- 1324_OPBG_2017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fragile X Syndrome
-
University of California, DavisNational Institute of Mental Health (NIMH)CompletedFragile X PremutationUnited States
-
University of California, DavisNational Institute on Aging (NIA); Forest LaboratoriesCompletedFragile X-Associated Tremor/Ataxia Syndrome | Fragile X Premutation CarriersUnited States
-
Ovid Therapeutics Inc.CompletedFragile X Syndrome (FXS)United States
-
Guido A. Davidzon, MD, SMWithdrawn
-
Marinus PharmaceuticalsUniversity of California, Davis; U.S. Army Medical Research and Development...Completed
-
RTI InternationalEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedFragile X Syndrome (FXS)United States
-
Novartis PharmaceuticalsTerminated
-
Sheba Medical CenterElMindA LtdRecruitingFragile X Associated Tremor-ataxia Syndrome | FXTASIsrael
-
University of California, DavisUniversity of Alberta; St. Justine's HospitalRecruitingNeurobehavioral Manifestations | Genetic Diseases, X-Linked | Intellectual Disability | Fragile X Syndrome | Sex Chromosome Disorders | Fragile X Mental Retardation Syndrome | Trinucleotide Repeat Expansion | Fra(X) Syndrome | FXS | Mental Retardation, X LinkedUnited States, Canada
-
University of AlbertaSt. Justine's HospitalRecruitingNeurobehavioral Manifestations | Genetic Diseases, X-Linked | Mental Retardation, X-Linked | Intellectual Disability | Fragile X Syndrome | Sex Chromosome Disorders | Fragile X Mental Retardation Syndrome | Trinucleotide Repeat Expansion | Fra(X) Syndrome | FXSCanada
Clinical Trials on Cooperative Parent Mediated Therapy" (CPMT)
-
University of California, Los AngelesSimons FoundationRecruitingAutism Spectrum DisorderUnited States
-
University of Wisconsin, MadisonCompletedParent-Child Relations | Autism Spectrum Disorder | MealsUnited States
-
University of Wisconsin, MadisonRecruitingParent-Child Relations | Autism Spectrum Disorder | MealsAustralia
-
Sabri HergünerNot yet recruitingAutism Spectrum Disorder | Behavior Problem of Childhood and Adolescence | EarthquakeTurkey
-
Jessica BrianIWK Health CentreCompletedAutism Spectrum DisorderCanada
-
Sabri HergünerCompletedAutism Spectrum DisorderTurkey
-
Instituto de Cardiologia do Rio Grande do SulCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Irmandade Santa...RecruitingChild Development | Congenital Heart Disease | Early InterventionBrazil
-
University of Dublin, Trinity CollegeFoundation for Medical Research; Friends of the Royal Hospital DonnybrookUnknownBalance | WeaknessIreland
-
Changi General HospitalNot yet recruiting
-
Memorial Sloan Kettering Cancer CenterWeizmann Institute of Science; Steba Biotech S.A.Active, not recruitingEsophagogastric Cancer | Moderate to Severe DysphagiaIsrael, United States